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Abstract
It is now well accepted that the structural protein Pr55
Gag is sufficient by itself to produce HIV-1 virus-like particles (VLPs).
This polyprotein precursor contains different domains including matrix, capsid, SP1, nucleocapsid, SP2 and p6. In the
present study, we wanted to determine by mutagenesis which region(s) is essential to the production of VLPs when Pr55
Gag
is inserted in a mammalian expression vector, which allows studying the protein of interest in the absence of other viral
proteins. To do so, we first studied a minimal Pr55
Gag sequence called Gag min that was used previously. We found that Gag
min fails to produce VLPs when expressed in an expression vector instead of within a molecular clone. This failure occurs
early in the cell at the assembly of viral proteins. We then generated a series of deletion and substitution mutants, and
examined their ability to produce VLPs by combining biochemical and microscopic approaches. We demonstrate that the
matrix region is not necessary, but that the efficiency of VLP production depends strongly on the presence of its basic
region. Moreover, the presence of the N-terminal domain of capsid is required for VLP production when Gag is expressed
alone. These findings, combined with previous observations indicating that HIV-1 Pr55
Gag-derived VLPs act as potent
stimulators of innate and acquired immunity, make the use of this strategy worth considering for vaccine development.
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Introduction
Virus-like particles (VLPs) have sparked an increasing interest
over the last decade [1,2]. These viral entities cannot perform a
full replication cycle and therefore cannot produce new progeny
virus. This property has allowed them to be used and studied in
different contexts. They serve notably in gene therapy investiga-
tions, as they can enter target cells and deliver a specific gene [3].
They are also employed for the study of chemical compounds that
can block particle assembly and could prove to be useful in
antiviral therapies. Finally, VLPs have recently been used with
success as a tool for vaccination against human papillomavirus
[4,5,6]. These recent successes underline the value of deepening
our understanding of the mechanisms involved in VLP formation
for many viruses, including human immunodeficiency virus type-1
(HIV-1).
HIV-1 can form VLPs by sole virtue of its Gag polyprotein
precursor, also known as Pr55
Gag. This structural viral constituent
is indeed the main actor in HIV-1 particle formation as it drives
assembly through protein-protein, protein-RNA, and protein-lipid
interactions, orchestrating the incorporation of each of the major
virus-encoded components into assembled particles [7,8,9,10].
Pr55
Gag is translated from unspliced viral mRNA on free
ribosomes in the cytoplasm and encodes the internal structural
components of the virion, i.e. matrix (MA), capsid (CA) and
nucleocapsid (NC) along with the C-terminal p6 domain and two
spacer peptides SP1 and SP2 [11]. In the absence of any other
viral proteins, Pr55
Gag can self-assemble into VLPs [12] by
ordered multimerization of monomers and/or oligomers to
produce a spherical shell, which forms the structural framework
of the immature virus particle [10,13]. It is noteworthy that HIV-1
Pr55
Gag-based VLPs elicit strong cellular and humoral responses
in non-human primate research models for AIDS [1,14,15].
Several regions of the Pr55
Gag polyprotein have been reported
to be crucial for particle formation. Notably, previous structural
and genetic analyses have demonstrated that the regions
responsible for membrane binding are located at the N-terminal
region of MA, which encompasses a cluster of basic residues and a
myristyl group interacting with acidic phospholipids of the
membrane [16,17]. However, several studies have shown that
MA can be largely deleted or even entirely replaced by a
heterologous myristyl anchor without compromising the formation
of extracellular viruses [18,19,20,21]. This suggests that the role of
MA in assembly is not as important as its role in Pr55
Gag
trafficking [22,23] and in the incorporation of virus-encoded
envelope glycoproteins (ENV) [24,25].
CA provides structural stability to HIV-1 particles and also
plays a key role in the formation of protein-protein contacts
required for a productive particle assembly. CA comprises two
globular domains: an N-terminal domain (NTD) and a C-terminal
PLoS ONE | www.plosone.org 1 Month 2011 | Volume 6 | Issue 11 | e28314domain (CTD) linked by a short flexible sequence [10,26,27]. The
NTD consists of five long helices forming a stable coiled-coil
structure, two more short helices, two hairpins, and a proline-rich
loop. NTD is considered to play a structural role in core formation
rather than actively driving particle production [18,19]. Indeed,
Gag lacking this entire domain was shown to assemble and bud
from the host cell [18,19]. However, previous studies have shown
that Gag constructs bearing certain specific mutations or in-frame
insertions in the N-terminal domain gave rise to a dramatically
reduced particle production even in the absence of the other viral
components, such as genomic RNA, envelope glycoproteins,
enzymes and auxillary proteins [28,29,30,31]. The authors
identified a previously unrecognized contiguous CA domain
located beneath the cyclophilin-A binding loop that participates
in Gag assembly. In contrast, CTD is recognized as being
fundamental for VLP formation. This specific region contains four
conserved helices and a highly conserved sequence among
retroviruses known as the major homology region (MHR) [11].
The MHR determines the Gag conformation required for efficient
protein-protein and protein-membrane interactions during virus
assembly [31,32,33]. Moreover, the hypothetical a-helix formed
by the last residues of CTD and SP1 participates in the assembly
process [34]. Mutations within the 14-amino acid peptide that
separates CA from NC or SP1 have been reported to induce
strongly aberrant budding structures and reduce the number of
released extracellular particles [31,35,36,37].
NC contains two zinc finger domains that bind RNA, and an
interaction domain (I domain), consisting in a stretch of basic
residues, that mediates Gag-Gag interactions [7,38]. Interestingly,
the zinc fingers are not absolutely necessary for the function of the
I domain [38,39,40]. Nevertheless, the role of RNA in assembly is
so vital that HIV-1 will recruit other cellular RNAs by default if
viral RNA is not available [41]. As far as the assembly process is
concerned though, NC can be efficiently replaced by a
heterologous leucine zipper (LZ) domain (i.e. a coiled-coil
sequence capable of forming parallel homodimers) [18,42,43].
The p6 domain contains two late domains (LDs), which are
required for pinching off the newly assembled virions from the
host membrane. The first one, located in N-terminal position, is
the principal LD. It contains a proline-rich PTAP motif, which
appears to play a critical role in exocytosis of assembled particles
[44]. PTAP interacts directly with Tsg101 [45], which is a host
component of the endosomal sorting complex required for
transport type-I (ESCRT-I) [46]. The second LD region located
in C-terminal contains a YPLTSL motif that interacts with
another cellular machinery molecule, i.e. AIP-1/ALIX (link
between ESCRT-I, and –II) [47]. It is well established that, in
some conditions, p6 can be replaced with a heterologous LD
sequence, notably with p2b, a small spacer peptide from another
retrovirus, i.e. Rous Sarcoma Virus (RSV), containing the PPPY
motif [18,48,49].
Although there are numerous bacterial, yeast and insect systems
to produce HIV-1-based VLP [1,2,15], the vast majority of VLP
studies using a mammalian system have been performed in a
provirus context [19,21,43]. Very few studies used solely the
Pr55
Gag polyprotein under the control of another promoter than
LTR, and obviously in the absence of virus auxiliary proteins. The
latter conditions moreover correspond to the common setup for
vaccine studies. Now, Accola and colleagues previously described
a minimal sequence of Pr55
Gag able to produce VLPs as efficiently
as wild type virus [18]. This chimera protein, expressed as part of a
molecular clone of HIV-1, was shown to be efficiently released
from host cells. In the present study, we show that a similar
minimal sequence can result in different experimental observations
when inserted in a mammalian expression vector instead of being
part of a molecular clone. Given this discrepancy, we investigated
further and, to do so, designed a series of Pr55
Gag mutants with the
aim of identifying which region(s) of Pr55
Gag are necessary to VLP
formation in our experimental approach. We examined expression
and VLP formation of these mutants by biochemical and electron
microscopy approaches and, in agreement with Accola and co-
workers, we demonstrate that MA is not necessary, and that NC
and p6 are dispensable when heterologous sequences like hCREB
and p2b are used. However, we observed that, in the context of a
mammalian expression vector, VLP formation requires the
presence of the NTD of the CA domain (amino acids 133 to
277) for assembly, budding and release in human human
embryonic kidney 293T (HEK293T) cells.
Results
We tested in this study the VLP-producing ability of a minimal
Pr55
Gag sequence inserted in a strong mammalian expression
vector, namely pcDNA3.1 (+). One of the major advantages of a
plasmid over a molecular clone for producing VLPs is that, most
evidently, the particles produced do not replicate, cannot revert to
an infectious virus, and are thus much safer. We decided to
evaluate a minimal Gag construct (called Gag min hereinafter)
that had already been reported in the literature by Accola and
colleagues [18]. This mutant was derived from the HXBH10-PR
-
molecular clone, which is identical to HXBH10, a Vpu-positive
variant of the HXB2 HIV-1 molecular clone, except for a point
mutation that inactivates the protease (PR) [18]. The chimera
protein was shown to be efficiently released from cells. It comprises
only 6 amino acids of the myristoylation signal in MA, only
residues 146 to 231 of CA, the 14 amino acids of SP1, and
heterologous sequences that replace NC and p6.
As illustrated in Fig. 1 (bottom line), our Gag min construct is
identical to the one previously described [18], except for the
heterologous NC sequence, which in our case consists in the
hCREB-1 sequence. This sequence forms a coiled-coil structure
capable of forming parallel homodimers. We decided to use this
basic LZ domain (bZIP) sequence instead of the yeast-derived
GNC4 sequence used previously [18] because, when formulating a
vaccine, one should avoid including foreign sequences in order not
to induce non-specific cross-immune reactions. Moreover, the
hCREB-1 sequence was successfully used in the past for the same
purpose [43]. Finally, to improve the efficiency of protein
translation in HEK293T cells, codons were humanized [50].
Gag min fails to produce VLPs
To determine how Gag min behaves in our VLP experimental
model system, this vector was first transiently transfected in
HEK293T cells as well Gag WT (used as a positive control). At
48 h post-transfection, cell-free supernatants containing VLPs
were harvested and transfected cells were collected as well, and
prepared as described in Methods section. Both VLPs and cell
lysates were analyzed on a gradient SDS-PAGE, and the gel was
next stained with Coomassie blue. As depicted in Fig. 2A, a major
band at a molecular weight (MW) of 55 kDa was observed for Gag
WT and, as expected, no similar protein signal appeared in the
cell-free supernatant from cells transfected with an empty control
vector (called mock). However, we failed to detect a band at the
predicted MW of Gag min (theoretical MW (MWth)=18.2 kDa)
in the cell-free supernatant. Too many bands were present in cell
lysis samples to allow identifying the different proteins of interest.
To achieve better sensibility and specificity, we performed
immunoprecipitation (IP) assays on the same samples with an
HIV-1 Virus-Like Particles Production
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technical strategy, we obtained for Gag min a specific signal at the
predicted 18.2 kDa in the cell lysate (Fig. 2B). However, we were
still unable to detect a signal in the cell-free supernatant, whereas
we detected a distinctive band for the positive Gag WT control.
At this point, we hypothesized that the Gag min protein was
being expressed by the transfected cell, but could not give rise to
VLP production due, for example, to a malfunction in the
assembly process. To explore this possibility, we analyzed our
transiently-transfected HEK293T cells by transmission electron
microscopy (TEM). For Gag min, we did not observe any VLP in
the process of budding through the cell membrane, or in the
supernatant close to the cell, in accordance with our previous
biochemical experiments (Fig. 2C). Moreover, there was no VLP,
whether incomplete or fully formed, in the cytoplasm of the
transiently transfected cells. This is in sharp contrast to Gag WT
that showed a characteristic VLP spherical morphology (average
size around 100 nm), similar to that of immature HIV-1 particles
[51].
To further investigate the intracellular location of the Gag min
proteins within the transfected cells, indirect immunofluorescence
studies were performed with an anti-p24 antibody. As illustrated in
Fig. 3 (upper panel), Gag WT proteins were detected throughout
the cytoplasm of transfected cells, organized in dotted structures
suggesting they were undergoing VLP assembly. In contrast, cells
transfected with the Gag min vector showed a more diffuse
Figure 1. Schematic representation of the different HIV-1 Pr55
Gag-derived constructs used in this study. The various molecular
constructs, derived from the HXB2 Pr55
Gag sequence (designated here as Gag WT), were made by PCR as described under the Materials and Methods
section. All constructs contain the wild-type myristic acid post-translational sequence in the N-terminal position and all were subcloned into the
pcDNA3.1 (+) eukaryotic expression vector. Wild-type HIV-1 sequences are denoted in black, and deleted virus sequences correspond to the dotted
line. Numbers above correspond to amino acids in the wild-type sequence. BR, basic region of MA; NTD, N-terminal domain; CTD, C-terminal domain.
doi:10.1371/journal.pone.0028314.g001
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panels). Thus, both biochemical and microscopy studies clearly
show that proteins expressed upon transfection of the Gag min
construct do not assemble properly when inserted within an
expression vector.
We next determine why this Gag min construct fails to form
VLPs in our experimental setting. Considering that it was designed
through investigations that almost always used full-length
molecular clones [18,19,21], we hypothesized that different
sequence stretches may be required for proper assembly of Gag
in the absence of all other viral proteins. We thus produced a series
of deletion mutants (Fig. 1), to re-examine the necessity of the
various Gag domains for producing VLPs, in the context of an
expression vector.
MA is not required for VLP production, but the basic
region allows a more efficient particle release
It is now well established that the MA region plays both
structural and targeting roles in the virus assembly process, but
appears to be somewhat less important in Gag multimerization.
The latter phenomenon relies largely on two key sequences. First,
the N-terminal myristyl acid has been demonstrated to interact
with the inner leaflet of the plasma membrane by hydrophobic
interactions [16,52,53,54]. Its absence prevents particle release
[22,23,55]. Second, the basic region (BR) (amino acids 18 to 33),
which is also located in the N-terminal position, plays a pleiotropic
role in the assembly process, notably in plasma membrane
targeting and binding. We thus produced two MA mutants
differing by the presence (MAD44–132) or the absence of BR
(MAD8–132) in order to investigate whether BR is required to
allow formation of VLPs. We detected the MA deletant proteins in
both the cell lysates and cell-free supernatants. Those proteins
were detected either with SDS-PAGE (Fig. 4A) or following
immunoprecipitation with an anti-p24 antibody (Fig. 4B). The
bands detected at 41 and 46 kDa respectively match the expected
molecular weight of MAD8–132 (Mwth=41.72 kDa) and
MAD44–132 (Mwth=46.02 kDa). However, the efficiency of
particle release proved to be different between these two mutants.
Indeed, MAD8–132 released about half as many particles as Gag
WT, whereas MAD44–132 released around 40% more than Gag
WT (Fig. 5). In other words, there is approximately a 3-fold
difference between these two mutants. Please note that, for
comparison purposes, Fig. 5 shows the relative efficiency of release
of VLPs for all mutants assayed in this study.
Figure 2. Gag min in the context of an expression vector fails to produce VLPs. (A) 293T cells were transfected with vectors expressing
either Gag WT or Gag min. The mock represents 293T cells transfected with the empty pcDNA3.1 (+) vector (used as a negative control). At 48 h post-
transfection, cell lysates (Cl) and cell-free supernatants (Sup) were analyzed on a gradient SDS-PAGE and the protein stained with Coomassie Brilliant
Blue. (B) In parallel, an IP assay was performed using an anti-p24 antibody on the same samples (Cl and Sup). Precipitated proteins were run on a
gradient SDS-PAGE and Gag proteins were analyzed by western blotting (WB) with a biotinylated anti-p24 antibody. (C) 293T cells expressing Gag WT
or Gag min construct were analyzed by TEM (magnification: 6 50,000). The Biochemical experiments shown are representative of at least three
independent experiments and two for the microphotographs.
doi:10.1371/journal.pone.0028314.g002
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and to examine the site of intracellular particle formation of the
two MA mutants, we performed TEM on HEK293T cells
expressing Gag WT, MAD8–132 and MAD44–132. An empty
control vector was also tested as well (data not shown). First,
morphological analysis of the two MA mutants confirmed their
typical VLP shape with spherical-like morphology and electron-
dense ENV (Fig. 6). In addition, for the MAD8–132 VLPs we
observed many points of intracellular assembly inside the
cytoplasm (bottom right). We however could not see this
phenomenon with the MAD44–132 VLPs, but rather more
numerous particles in the extracellular space (bottom left). These
observations confirm the discrepancy in particle release between
these two MA mutants. Globally, the results above show that the
MA domain can be dispensable for VLP formation, although the
basic region seems to promote particle production efficiency.
NC and p6 regions are required for VLP release, although
they can be replaced with heterologous sequences
hCREB and p2b
We next investigated the possible contribution of NC and p6
domains in VLP formation. According to the literature, the p6
domain is important in the final release process from infected
cells, whereas NC participates in Gag-Gag interactions [46,56].
We thus designed the deletion mutants Dp6 and DNCp6 as
illustrated in Fig. 1. As with VLPs produced from molecular
clones [42,43], the NC and p6 deletion constructs were unable to
produce VLPs. Indeed, cell-free supernatant analysis of trans-
fected HEK293T cells did not permit to detect any protein
signal, be it with SDS-PAGE (Fig. 7A) or following an IP/
western blot assay (Fig. 7B). However, the two deletion mutants
were clearly expressed because we were able to detect protein
signals in cell lysate fractions. Respective molecular weights of 41
and 50 kDa were detected for DNCp6 (Mwth=41.91 kDa) and
Dp6 (Mwth=50.14 kDa). Results from TEM analyses allowed us
to confirm a default in VLP release for those two different
constructs (Fig. 7C) (data not shown for the Gag WT control).
The Dp6 mutant shows a pinching-off default, as VLPs remain
tethered to the cell plasma membrane. On the other hand,
DNCp6 showed an intriguing morphology. Indeed, VLP
formation and assembly occur close to the inner leaflet of the
plasma membrane, but the particles seem to accumulate at the
membrane in large quantities, while showing no sign of
pinching-off (Fig. 7C, bottom left).
Figure 3. Gag min proteins show a diffuse distribution pattern. 293Tcellswere transfectedeither withGagWT(upperpanels),Gagmin (middle
panels)orpcDNA3.1(+) vector(bottompanels).At 48 h post-transfection, cellswerefixedandpermeabilizedforimmunofluorescenceassaysasdescribed
in Materials and Methods. Nuclei were stained with DAPI. White arrows indicate a punctiform distribution of Gag proteins. The samples were visualized
with a Nikon eclipse TE 300 inverted microscope (magnification: x 1,000). The experiment shown is representative of 3 independent experiments.
doi:10.1371/journal.pone.0028314.g003
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VLP model. Moreover, we evaluated if heterologous sequences
were able to efficiently substitute NC and p6 domains, like they
can when Gag is expressed in a molecular clone [18]. We designed
2 substitution mutants, p6449LD and NCp6378LZLD. Concerning
p6449LD, this construct differs from the Gag WT only by the
substitution of the p6 domain with the RSV p2b sequence (see
introduction section for more details). Overall, p6449LD was
expressed intracellularly and produced VLPs to a similar extent as
the Gag WT (release efficiency of about 1.4 fold compared to Gag
WT) (Fig. 5). The p6449LD protein signal was detected both by
SDS-PAGE and western blot assays (Figs. 7A and 7B) with a
50 kDa molecular weight (Mwth=51.18 kDa). TEM data showed
that the morphology of p6449LD VLPs (Fig. 7C, upper right panel)
is comparable to that of the Gag WT (data not shown).
Next, to get closer to the structure of the Gag min construct, we
performed a double substitution where, in addition to replacing p6
with p2b, we replaced NC and SP2 by hCREB-1. As expected, the
resulting NCp6378LZLD mutant was able to generate VLPs,
which were released efficiently from cells (Figs. 7A and 7 B). This
was confirmed by TEM (Fig. 7C, bottom right) (1.4 fold compared
to Gag WT) (Fig. 5). Taken together, the above substitutions and
deletions in our VLP model confirm that both NC and p6 are
required for particle release. In addition, their substitution with
heterologous sequences does not diminish the efficiency of the Gag
plasmid.
N-terminal domain of CA is necessary for VLP formation
The last domain remaining to be investigated was the CA
protein. We focused our attention on the NTD because the CTD
has been recognized as essential to the particle assembly process.
On the other hand, controversial results have been obtained with
NTD, as explained in the introduction section. Thus, we designed
a CA NTD mutant where the complete NTD region (amino acids
133 to 277) was deleted like in the Gag min mutant. This new
mutant named CADNTD at first sight appeared to be able to
produce VLPs efficiently as shown both by SDS-PAGE and IP/
western blot (Figs. 8A and 8B). However, in contrast to previous
studies, the morphological characterization failed to confirm that
our protein gel results correspond to bona fide VLP. In fact, this
mutant showed a severe default in the assembly and budding
process (Fig. 8C). Nevertheless, this finding is consistent with
previous observations made in baculovirus-infected cells by Chazal
and colleagues where a Gag insertion mutant at position 209
resulted in a very similar cellular membrane phenotype [28]. Our
CADNTD mutant actually shows very large electron-dense
patches of the Gag mutant protein at deformed areas of the
plasma membrane.
In conclusion, the CADNTD mutant was unable to form VLPs
in our hands. We hypothesize that the supernatant protein signals
detected biochemically may correspond partially to cell-free
patches of cell plasma membrane containing densely-aggregated
Gag mutant proteins.
Discussion
In the present work, we designed a series of Pr55
Gag mutants
with the aim of defining, in the context of a mammalian expression
vector, the intrinsic role of the Gag protein in the assembly and
release of immature VLPs from human producer cells. Past
investigations almost always used full-length molecular clones in
which a point mutation inactivated the viral protease gene in order
to produce immature HIV-1 particles [18,19,21]. However, using
these molecular constructs, one cannot exclude the influence on
the assembly process of other viral gene components like ENV or
accessory molecules. Those viral accessory proteins are not
desirable when investigating Gag auto-assembly. Also, working
with mammalian expression plasmids presents a number of other
advantages, as compared to a full-length molecular clone. For
example, smaller plasmids are easier to handle. More importantly,
the particles produced have no possibility of replication and
cannot revert to an infectious virus. We thus studied VLP
formation in the complete absence of the other viral proteins, in
the perspective of gathering valuable information for future
vaccine design.
To achieve this goal, we expressed the precursor Pr55
Gag
polyprotein under a promoter different from the HIV-1 LTR in a
mammalian expression vector. On the basis of biochemical and
microscopical data, we found that, in contrast to previous
published observations [18], the minimal Gag chimera protein
failed to produce VLPs. In fact, we were unable to detect viral
protein in the supernatant, nor any budding structures in TEM
Figure 4. MA region is not required for VLP production. (A) 293T
cells were transfected either with Gag WT, MA mutants (i.e. MAD8–132
and MAD44–132) or pcDNA3.1 (+) vector. At 48 h post-transfection,
both the cell lysates and cell-free supernatants were analyzed on a
gradient SDS-PAGE with Coomassie Brilliant Blue staining. (B) In parallel,
an IP assay was performed using the anti-p24 antibody on the same
samples. Precipitated proteins were run on gradient SDS-PAGE and Gag
proteins were analyzed by Western Blotting (WB). The Biochemical
experiments shown are representative of at least three independent
experiments.
doi:10.1371/journal.pone.0028314.g004
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the studied HIV-1 Pr55
Gag-derived plasmids were quantified by scanning the band densities on the WB membranes using a Typhoon 9200 fluorescent
laser scanner. Ratios of total Gag protein levels in the cell-free supernatants to those in cells extracts were determined for each construct, and
compared with the same ratio for Gag WT. Results shown were obtained by dividing the release ratio for each mutant by the ratio for the Gag WT and
multiplying by 100. Data shown represent at least three independent experiments for each mutant. Error bars indicate standard deviations.
doi:10.1371/journal.pone.0028314.g005
Figure 6. The Basic Region of MA allows a more efficient particle release. 293T cells expressing either Gag WT or MA mutants (i.e. MAD8–
132 and MAD44–132) were examined by TEM (magnification: 6 50,000). The microphotographs shown are representative of 2 independent
experiments.
doi:10.1371/journal.pone.0028314.g006
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cells, because we were able to detect a signal by western blot and
indirect immunofluorescence microscopy (Figs. 2 and 3). In
addition, we detected the mRNA by RT-PCR in cell extracts
(data not shown). The failure seems to happen early in the
assembly process, as illustrated by the very diffuse signal appearing
in microphotographs (Fig. 3). It could consist in a major
preassembly default. This sharply contrasts with the Gag WT
proteins that display a punctate staining pattern, a phenotype in
accordance with previous studies [57,58,59,60]. These sites of
intense Gag localization presumably represent active centers of
virus assembly. Characterization of such sites will provide
additional insights into the mechanism of Gag trafficking and
virus assembly.
Our results though do not necessarily contradict those of Accola
and colleagues [18], as the noted discrepancies can be explained
by numerous factors. First, the authors worked with a different
expression system, which was based on the HXBH10-PR
-
molecular clone, and, as stated above, the presence of all virus
proteins may influence the action of the Gag protein during VLP
production. Second, we used a different dimerization domain since
we substituted the previously used GCN4 sequence by the hCREB
leucine zipper domain. Although this sequence had already proven
to efficiently replace NC in a previous work [43], we cannot rule
out the possibility that hCREB and GCN4 differently affect VLP
formation. However, it must be noted that the substitution of NC
by hCREB did not modify VLP production in our assays. Third,
Accola and co-workers used only biochemical approaches in their
study. They did not provide any electron microscopic studies in
their work. Therefore, a direct visual comparison with our
observations is lacking. Most importantly, it is our TEM studies
that allowed us to detect a default in assembly and budding of the
CADNTD mutant, whereas biochemical approaches indicated
VLP production. Fourth, the authors used different methods for
detecting VLPs in cell lysates and in supernatants; for the latter,
they used
35[S] methionine metabolic labelling, a method well-
known for its sensitivity, whereas they performed a classical WB on
cell lysates. On the other hand, we revealed the Gag protein with a
biotinylated monoclonal antibody against p24 and the primary
antibody was detected with Cy-3-conjugated streptavidin technol-
ogy both for cell lysates and VLP with the aim of keeping the same
detection method for the two types of samples.
In our quest to determine the reason(s) why Gag min does not
produce VLPs, we designed a series of mutants/deletants derived
from Gag WT and Gag min in order to find out which domain(s)
appears to be essential to produce VLPs in our conditions. We
confirmed that, at least under our experimental conditions, the
MA domain is dispensable for VLP formation as long as two
fundamental elements are present: (1) the myristyl acid in the MA
N-terminal position that interacts with the inner leaflet of the
plasma membrane by hydrophobic interactions [16,52,53,61].
The absence of this myristyl acid prevents particle release
[22,23,55]; (2) the basic region (BR: 18–33) in the MA N-terminal
position, that fulfills multiple functions in assembly process, like
plasma membrane targeting and binding [54,59,61,62]. Indeed,
MAD44–132 is efficiently produced like depicted in Fig. 4 and is as
efficiently released as Gag WT.
In comparison, the MAD8–132 mutant, in which almost the
totality of MA was deleted, is still able to produce VLPs, but less
efficiently than Gag WT or MAD44–132. We observed through
microscopy that this mutant lacking the BR region presents partial
virus assembly and that assembly is redirected from the plasma
membrane to intracellular membranes (Fig. 6) [54,61,63]. More
precisely, we can suggest here that, like Ono et al. have already
reported [33], assembly of BR-deficient mutant partially takes
place in Golgi or post Golgi vesicles.
Concerning the NC and p6 substitutions, we are in agreement
with previous studies that demonstrated the importance of these
two domains for VLP production. It seems clear that the deletion
of p6 results in severe defaults in VLP release, which is in
Figure 7. Domains NC and p6 are required for VLP release,
although they can be replaced with heterologous hCREB and
p2b sequences. (A) 293T cells were transfected either with Gag WT or
expression vectors encoding for NC or P6 mutants (i.e. Dp6, DNCp6,
p6449LD and NCp6378LZLD). At 48 h post-transfection, cell lysates and
cell-free supernatants were analyzed on gradient SDS-PAGE and protein
stained with Coomassie Brilliant Blue. (B) In parallel, an IP assay was
performed using the anti-p24 antibody on the same samples.
Precipitated proteins were run on SDS-PAGE and Gag proteins were
analyzed by WB. (C) Transfected 293T cells were analyzed by TEM
(magnification: 6 50,000). The Biochemical experiments shown are
representative of at least three independent experiments and two for
the microphotographs.
doi:10.1371/journal.pone.0028314.g007
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displays a classical VLP morphology, assembling at the plasma
membrane, the particles appear unable to pinch off the cell
membrane. They seem to remain tethered to the cell surface,
which implies the necessity of a late domain that is able to interact
with ESCRT complexes for efficiently budding out of the cells
[8,9,46]. On the other hand, we obtained for the DNCp6 mutant
results somewhat different from previously published ones. As
depicted in Fig. 7C, Gag seems to assemble directly underneath
the plasma membrane, in contrast to the formation of large
patches of Gag already described [42]. Considering that the
DNCp6 mutant consists in MA, CA and SP1, it is not surprising
that the targeting of the protein to the plasma membrane is
occurring. The CA region, along with the adjoining SP1 14 amino
acids, may adopt a hypothetical a-helix conformation. This region
is well known to mediate strong Gag-Gag interactions, leading to
higher-order multimerization critical for particle assembly.
Therefore, the morphology observed in this TEM study for the
DNCp6 mutant agrees with its expected properties.
Now,concerningthe double substitution mutant NCp6378LZLD,
it is released efficiently from HEK293T cells as confirmed by the
TEM results. This agrees with previous substitutions of p6 with the
RSV p2b region [48], and of NC with a heterologous LZ domain
[43]. It is noteworthy that for replacing NC, instead of the GCN4
yeast sequence used in Gag min by Accola et al. we selected the
hCREB sequence, a sequence successfully used previously for the
same purpose [43]. Indeed, in the perspective of the VLPs being
used in vaccine preparations, we preferred to avoid including an
exogenous domain, which can interfere with the immune VLP
specific response. Moreover, to the best of our knowledge, this is the
first such double substitution of NC and p6, in an otherwise intact
Gag.
Finally, the most noteworthy mutant in this study is CADNTD,
in which the N-terminal domain is entirely deleted. With
biochemical methods, we were able to detect, as expected, a
protein signal for CADNTD, both in the cell lysate and
supernatant, indicating that this mutant was able to produce
VLPs. Remarkably however, electron microscopy showed a total
absence of VLP formation, either intracellularly or extracellularly
(Fig. 8C). We suggest that the supernatant protein signals detected
biochemically may correspond partially to cell-free patches of cell
plasma membrane containing densely-aggregated Gag mutant
proteins and not bona fide VLPs. However the cellular release of
microvesicles and/or exosomes cannot be totally excluded even
though this scenario is not supported by our TEM data.
Additional studies are warranted to validate this postulate. This
Figure 8. Domains NC and p6 are required for VLP release, although they can be replaced with heterologous hCREB and p2b
sequences. (A) 293T cells were transfected either with Gag WT or expression vectors encoding for NC or P6 mutants (i.e. Dp6, DNCp6, p6449LD and
NCp6378LZLD). At 48 h post-transfection, cell lysates and cell-free supernatants were analyzed on gradient SDS-PAGE and protein stained with
Coomassie Brilliant Blue. (B) In parallel, an IP assay was performed using the anti-p24 antibody on the same samples. Precipitated proteins were run
on SDS-PAGE and Gag proteins were analyzed by WB. (C) Transfected 293T cells were analyzed by TEM (magnification: 650,000). The Biochemical
experiments shown are representative of at least three independent experiments and two for the microphotographs.
doi:10.1371/journal.pone.0028314.g008
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is dispensable for VLP production [18,19], but rather plays a role
in the rearrangement of different Gag components during the
maturation process. We are currently investigating the reasons
why the CA NTD appears to be important in VLP production at
least under our experimental settings. It may be that the NTD
region allows weak interactions with the CTD during virus
assembly as suggested by a previous study [31]. The authors
clearly demonstrated that point mutations in helices 4–6 greatly
reduce viral production. It is also possible that these mutations
disrupt the overall folding of CA. The structure of full-length HIV-
1 CA has been previously depicted by Ganser-Pornillos and
colleagues [10,64] and it was shown that NTD-NTD forms the
hexamerisation interface, whilst CTD-CTD forms the dimeriza-
tion interface, and that an additional interface exists between
NTD and CTD in a mature CA context. This might help to
explain why deletion of the CA NTD prevents VLP formation.
In conclusion, the observed requirement of NTD for Gag-Gag
interaction and consequently for Gag assembly may explain the
failure of Gag min to lead to VLP formation in our experimental
setting. Therefore, we believe that a better understanding of
mechanisms underlying VLP production will help the scientific
community in future design of VLP-based HIV-1 vaccines.
Methods
Pr55
Gag molecular constructs
Gag sequences were derived from the hGag-TAP construct (i.e.
HXB2-based vector) (GenBank K03455) in which codons were
humanized [65]. Gag fragments were PCR amplified with Taq
Hi-Fi (Invitrogen, Burlington, Canada) from the hGag-TAP
construct and cloned into the pcDNA3.1 (+) vector (Invitrogen,
Burlington, Canada) using HindIII (forward) and EcoRI (reverse)
restriction sites present in respective PCR primers (restriction sites
are underlined in the following primer sequences). We constructed
a series of mutant Pr55
Gag expression plasmids as depicted in
Fig. 1. In brief, the Gag wild-type (Gag WT) sequence was
amplified using forward primer 59-CCC AAG CTT ATG GGC
GCC CGC GCC AGC and reverse primer 59-CCG GAA TTC
TCA TTG TGA CGA GGG GTC GCT GC. The MAD8–132
construct involved deletion of the MA domain except for the
myristylation signal sequence included in the forward primer
(shown in italic): 59- CCC AAG CTT ATG GGC GCC CGC GCC
AGC GTG CCC ATC GTG CAG AAC ATC CAG. The reverse
primer was the same one as for the Gag WT construct. In the
p6449LD construct, the p6 domain was replaced by a LD
sequence derived from the RSV p2b domain [48], which consists
of a TASAPPPPYVG motif in the expressed protein. The
corresponding motif sequence was introduced in the reverse
primer (shown in italic). The forward primer used was the same as
for Gag WT construct, and the reverse primer was 59- CCG GAA
TTC TCA GCC CAC GTA GGG AGG TGG AGG GGC GCT GGC
GGT AAA ATT CCC TGG CCT TCC CTT G. For the
MAD44–132 construct, fragment 1 was amplified using the
forward primer used for the Gag WT construct. The reverse
primer contained the sequences corresponding to the beginning of
the CA domain (underlined in the text) and to the end of the basic
region sequence (shown in italic): 59- CTG GAT GTT CTG CAC
GAT GGG GCG CTC CAG CTC GCG GCT G. For fragment 2, the
forward primer contained the end of the basic region domain
sequence (shown in italic) and the beginning of the CA domain
sequence (underlined in the text): 59-CAGC CGC GAG CTG GAG
CGC CCC ATC GTG CAG AAC ATC CAG. The reverse primer
was the same one as for the Gag WT construct. The two fragments
were combined in a fusion PCR reaction (see Dp6 construct below)
using forward and reverse primers used for the Gag WT construct.
For the NCp6378LZLD construct, fragment 1 was PCR amplified
with the forward primer used for Gag WT construct. The reverse
primer contained the sequence corresponding to the beginning of
the LZ domain (underlined in text) from the CREB gene and the
end of the SP1 spacer (shown in italic): 59- TTT CTT CTT TCT
ACG ACA CTC TCG CAT GAT GGT GGC GCT GTT GGT C.
For fragment 2, the DNA template used was the plasmid
KCREB1 provided generously by Dr. R. H. Goodman (Vollum
Institute, Portland, USA). The forward primer contained the end
of the SP1 sequence (shown in italic) and the beginning of the LZ
sequence (underlined in the text): 59- G ACC AAC AGC GCC ACC
ATC ATG CGA GAG TGT CGT AGA AAG AAG AAA. The
reverse primer contained the sequence corresponding to the end of
LZ region (underlined in the text), a sequence coding for LD
(shown in italic) humanized according to a previously published
code [50] and the restriction site for EcoRI (underlined in the text):
59- CCG GAA TTC TCA GCC CAC GTA GGG AGG TGG AGG
GGC GCT GGC GGT ATC TGA TTT GTG GCA GTA AAG G.
The two fragments were combined in a fusion PCR (see Dp6
construct below) using the forward primer used for fragment 1
amplification and the reverse primer used for fragment 2
amplification. For the CADNTD construct, fragment 1 was
amplified using the forward primer used for the Gag WT
construct. The reverse primer contained the sequences corre-
sponding to the beginning of the CA MHR domain (underlined in
the text) and to the end of the MA domain (shown in italic): 59-
GTC CAG GAT GCT GGT GGG GCT GTA GTT CTG GCT
CAC CTG GTT G. For fragment 2, the forward primer contained
the end of the MA domain (shown in italic) and the beginning of
the CA MHR domain (underlined in the text): 59- C AAC CAG
GTG AGC CAG AAC TAC AGC CCC ACC AGC ATC CTG
GAC. The reverse primer was the one used for the Gag WT
construct. The 2 fragments were combined in a fusion PCR
reaction (see Dp6 construct below) using forward and reverse
primers used for the Gag WT construct.
The Gag min construct was based on published work
describing the minimal Gag sequence required to generate VLPs
[18]. Fragment 1 was amplified with a forward primer containing
a HindIII restriction site (underlined in the text), a myristylation site
(shown in italic) and the beginning of the CA MHR domain
(underlined in the text): 59- CCC AAG CTT ATG GGC GCC CGC
GCC AGC GTG AGC CCC ACC AGC ATC CTG GAC. The
reverse primer contained the sequences corresponding to the
beginning of LZ domain (underlined in the text) and to the end of
the SP1 sequence (shown in italic): 59- TTT CTT CTT TCT
ACG ACA CTC TCG CAT GAT GGT GGC GCT GTT GGT C.
For fragment 2, the template DNA used was the KCREB1
plasmid. The forward primer contained sequences corresponding
to the end of SP1 (underlined in the text) and to the beginning of
the LZ domain (shown in italic): 59- G ACC AAC AGC GCC
ACC ATC ATG CGA GAG TGT CGT AGA AAG AAG AAA. The
reverse primer was the same one as for the NCp6378LZLD
construct. The 2 fragments were combined in a fusion PCR using
the forward primer used for fragment 1 and the reverse primer
used for fragment 2.
For both Dp6 and DNCp6 constructs, the forward primer was
the same one as for the Gag WT construct. The reverse primer
used for the Dp6 construct was 59- CCG GAA TTC TCA AAA
ATT CCC TGG CCT TCC CTT G. The reverse primer used for
the DNCp6 construct was 59- CCG GAA TTC TCA CAT GAT
GGT GGC GCT GTT GG. Chimeric sequences were generated
by fusion PCR. Briefly, two fragments were PCR amplified using
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for future annealing to the beginning of fragment 2 and the
forward primer of fragment 2 contained a sequence for future
annealing to the end of fragment 1. Both PCR products were
purified on DNA-binding columns (Qiagen, Mississauga, Canada).
Then, 2.5 ml of each purified fragment were combined with a
master mix containing Taq Hi-Fi buffer, MgSO4, dNTPs and Taq
Hi-Fi. Five cycles of PCR amplification were completed under
these conditions. During the denaturation step of cycle 5, primers
were added: a forward primer containing the HindIII restriction
site annealing to the beginning of fragment 1, and a reverse primer
containing the EcoRI restriction site annealing with the end of
fragment 2. Next, 25–30 additional cycles were completed. The
fusion PCR product was purified on agarose gel, then digested
with HindIII and EcoRI and cloned into vector pcDNA3.1 (+).
Cell culture and transfection
The HEK293T cell line was used to produce VLP stocks. This
cell line was obtained from the American Type Culture Collection
(Manassas, VA) and maintained in Dulbecco’s modified Eagle
medium (DMEM) (Invitrogen, Burlington, Canada) supplemented
with 10% heat-inactived foetal bovine serum (Invitrogen,
Burlington, Canada), penicillin G (100 U/ml), and streptomycin
(100 mg/ml) at 37uCi n5 %C O 2. For calcium phosphate
transfection, the various plasmids were transfected in 40–50%
confluent HEK293T cells in T75 cm
2 flasks (BD, Oakville,
Canada), as described previously [66,67]. Briefly, fifteen micro-
grams of plasmid were used to transfect HEK293T cells and at 6 h
post-transfection, the medium was discarded and cells washed
twice with phosphate-buffered saline (PBS). Finally, 10 ml of fresh
medium was added and the cells were incubated for an additional
48 hours.
Preparation of cell lysates and VLP supernatants
Cell supernatants were collected 48 h post-transfection, centri-
fuged at 4uC for 5 min at 3006g, and filtered through a 0.22 mM
pore-size cellulose acetate membrane to remove cellular debris
(ThermoFisher Scientific, Ottawa, Canada). For virus release
assays, the cell-free supernatants were centrifuged through a 2 ml
20% sucrose cushions in TSE (10 mM Tris hydrochloride
[pH 7.5], 100 mM NaCl, 1 mM EDTA) at 4uC for 45 min at
274,000 6 g (SW41 rotor at 40,000 rpm; 2 ml of cushion for
10 ml of supernatant from each T75 cm
2 flask) [21]. The pellets
were then resuspended in 150 ml of immunoprecipitation buffer
(IPB) (20 mM Tris hydrochloride [pH 7.4], 50 mM NaCl, 1%
Triton X-100) containing a protease inhibitor cocktail (Thermo-
Fisher Scientific, Ottawa, Canada). The samples were aliquoted
and stored at 280uC. As for the transfected cells, they were
washed once with 10 ml of room temperature PBS, detached with
10 ml of ice-cold PBS, and pelleted with a brief centrifugation at
4uC for 5 min at 300 6g. The cell pellets were lysed in 1 ml of
IPB containing protease inhibitors, followed by a brief vortexing
and microcentrifugation at 4uC for 5 min at 13,0006g to remove
insoluble materials. Cell lysates were aliquoted and stored at
280uC. All cell lysate samples were normalized with BCA protein
quantification assays (Thermo Fisher Scientific, Ottawa, Canada).
Gradient SDS-PAGE and Coomassie blue staining
Normalized quantities of cell lysates or VLP supernatants were
mixed with an equal volume of 2X sample buffer (125 mM Tris
hydrochloride [pH 6.8], 4% sodium dodecyl sulfate (SDS), 20%
glycerol, 3.1% dithiothreitol (DTT), 0.25% bromophenol blue),
and boiled for 5 min at 100uC. Samples were left to migrate
on a 7.5–20% gradient SDS-polyacrylamide gel electrophoresis
(PAGE). Thereafter, the gels were incubated for 15 min in
Coomassie Brilliant Blue (Bio-Rad laboratories, Mississauga,
Canada) (0.4% R250, 10% acetic acid, 30% methanol), and then
discoloured in a mixture of 10% acetic acid and 30% methanol.
Gels were digitized with a scanner (SnapScan e20, AGFA).
Benchmark Standard ladder protein was used (Invitrogen,
Burlington, Canada).
Immunoprecipitation (IP) and Western blots analyses
To precipitate the Gag protein, we used the monoclonal
antibody specific for the major core capsid protein p24 purified
from the 183-H12-5C hybridoma (AIDS Repository Reagent
Program, Germantown, USA). Briefly, 5 mg of 183-H12-5C
antibody were added to cell lysates or cell-free supernatants at
4uC for at least 30 min on a rotary shaker (Labquake, Thermo
scientific, Ottawa, Canada). Next, 30 ml of protein A/G plus-
Agarose (Santa Cruz Biotechnology, Santa Cruz, USA) were
added, and agitated at 4uC for 1 h on a rotary shaker. Next, four
washes were done with IPB, followed by microcentrifugation at
4uC for 30 sec at 13,200 6 g. Finally, pellets were resuspended
with an equal volume of 26 sample buffer (125 mM Tris
hydrochloride [pH 6.8], 4% sodium dodecyl sulfate (SDS), 20%
glycerol, 3.1% dithiothreitol (DTT), 0.25% bromophenol blue).
After boiling for 5 min, the samples were microcentrifuged for
1 min at 13,000 6 g and transferred to a new tube in order to
eliminate beads. Samples were left to migrate on gradient SDS-
polyacrylamide gel as described above.
After SDS-PAGE migration, proteins were transferred onto
Immobilon-P PVDF 0.45 mM membranes (Thermo Fisher
Scientific, Ottawa, Canada) by standard blotting technique.
Proteins were revealed with a biotinylated anti-p24 antibody
(183-H12-5C hybridoma) (EZ-link sulfo-NHS-LC-Biotin Thermo
Fisher Scientific, Ottawa, Canada). Primary biotinylated antibod-
ies were detected with Cy-3-conjugated streptavidin (Jackson
ImmunoResearch Lab, Inc) at a working concentration of 0.5 mg/
ml. Fluorescent signal detection was achieved by scanning the
membrane with a fluorescent laser scanner Typhoon 9200 (GE
Healthcare Canada, Mississauga, Canada). In order to determine
the protein’s molecular weight, the standard protein ladder used
was the ECL Plex Fluorescent Rainbow markers (GE Healthcare
Canada, Mississauga, Canada). HIV-1 Gag proteins immunode-
tected on membranes were quantitated with ImageQuant version
5.2 software, and background correction (local average) was
applied for all conditions tested. Graphic was normalized with
Pr55
Gag wild-type proteins (WT) and expressed as a percentage of
WT.
Electron microscopy
HEK293T cells were transfected with the studied VLP
constructs as described above. The cells were harvested 48 h
post-transfection, fixed in a solution of 0.1 M cacodylate buffer
containing 8% sucrose and 2.5% glutaraldehyde, washed in the
same buffer overnight, and then post-fixed with 1% osmium
tetroxide at 4uC for 90 min. Dehydration with graded ethanol was
then performed, and the cell samples were embedded in Eponate
resin (Poly/Bed 812; Polysciences, Burlington, Canada). Sections
of 60–80 nm were stained with uranyl acetate and lead citrate, and
observed under a JEOL 1010 TEM at a magnification of 50,000,
Digital images were processed with the Gatan digital micrograph
software version 3.10.1.
Indirect immunofluorescence assays
Prior to transfection, cells (1610
4) were plated in 24-well plates
(BD, Oakville, Canada) containing German Glass coverslips
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calcium phosphate protocol described above; 48 h post-transfec-
tion, cells were washed twice with PBS, fixed in 4% paraformal-
dehyde (PFA) at room temperature for 20 min, and washed four
times with PBS. Cells were incubated for 30 min with blocking/
permeabilization buffer (1% bovine serum albumin (BSA), 0.1%
Triton X-100, and 10% human heat inactivated serum (HHIS)).
After four additional washes with PBS, cells were stained with the
anti-p24 183-H12-5C antibody. Following washes with PBS, cells
were incubated with an Alexa 488-conjugated goat anti-mouse
secondary antibody (Invitrogen, Burlington, Canada) and, finally,
the nuclei were stained with 49,6-diamidino-2-phenylindole
(DAPI) provided by Invitrogen (Burlington, Canada). After several
washes, slides were mounted in Fluoromount G (Invitrogen,
Burlington, Canada). The samples were visualized using a Nikon
eclipse TE 300 inverted microscope at a 1000X magnification.
Digital images were processed with ImageJ software, version 1.42q
(NIH, rsbweb.nih.gov/ij).
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